Entity reinforces that personalized preparations are essential when industrialized products do not meet clinical needs

New regulation simplifies registration and expands the use of biodiversity in herbal medicines, as soon as cannabis products are classified as medicines, they must comply with these standards.

Pharmaceutical company Ephar has obtained registration for its Cannabidiol in two concentrations, 50 mg/mL and 100 mg/mL, which will be marketed in a low THC content drop solution

According to Marcelo Polacow Bisson, excluding pharmacies' manipulation leads to lack of assistance; Anvisa's proposed text on the Cannabis regulation is also criticized for bypassing procedural rites

How the pharmaceutical industry ensures quality and safety in cannabis-based products sold in Brazil

Gustavo Palhares believes that regulatory review could streamline prescription, expand access, and raise technical requirements in the medical cannabis sector

Curitiba welcomes its first exclusive medicinal cannabis pharmacy, in a market that grew from R$ 38.5 million in 2022 to R$ 237.8 million in 2025, while Paraná accounts for only 2.4% of sales, indicating great potential in the state with 11 million inhabitants

Lecture led by specialist will address scientific updates, clinical use, and regulation of cannabinoid therapies in Dentistry during the event in São Paulo

Planning to travel at the end of the year and using medical cannabis? Learn about the required documents, how to transport the medication, and what precautions to take in Brazil and abroad

Pharmaceutical company Farmausa Life Science has obtained registration for its Cannabidiol in two concentrations, 20 mg/mL and 100 mg/mL, with low THC content

Cannten's extract with 71.33 mg/mL expands medicinal treatment options in the country and receives authorization for commercialization

Endogen's extract expands the portfolio of options for medicinal treatments and already has sanitary authorization for commercialization

Financial consolidation, cultivation regulation, and strengthening of events mark the sector's prospects for the next year

Approved document defines 161 priority topics for the next two years, including national cultivation of low-THC cannabis

Preventive action involves imported and national items and reinforces rules for restricted disclosure to doctors and pharmacists

With limited spots available, Cannabis Connection 2025 will host the launch of the 5th Sechat Cannabis Guide and discussions on regulation, cultivation, and market

New authorization expands university's scope in Reblas and reinforces quality control of plant derivatives in the national market

Studies show efficacy of cannabinoids in controlling inflammation, acne, and itching, while Anvisa evaluates expanding regulations for topical products

The Australian medicinal cannabis market is consolidating as an international reference and inspiring discussions in Brazil

Population and regulated sectors have the opportunity to indicate topics of interest for the next biennium